Publikasjoner fra NKB

En fortløpende publikasjonsliste fra forskere ved NKB.

2017

Clinical milestones in Parkinson’s disease: A 7-year population-based incident cohort study.
Bjornestad, Pedersen, Tysnes OB, Alves G.
Parkinsonism Relat Disord. 2017 May 29. pii: S1353-8020(17)30191-8. doi: 10.1016/j.parkreldis.2017.05.025.

Neurofilament light: A heavyweight diagnostic biomarker in neurodegenerative parkinsonism?
Alves G, Bonanni L.
Neurology. 2017 Mar 7;88(10):922-923. doi: 10.1212/WNL.0000000000003699.

Is fatigue associated with cognitive dysfunction in early Parkinson’s disease?
Kluger BM, Pedersen KF, Tysnes OB, Ongre SO, Øygarden B, Herlofson K.
Parkinsonism Relat Disord. 2017 Feb 7. pii: S1353-8020(17)30040-8. doi: 10.1016/j.parkreldis.2017.02.005.

Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.
Pedersen KF, Larsen JP, Tysnes OB, Alves G.
Neurology. 2017 Jan 20. pii: 10.1212/WNL.0000000000003634.

2016

Long-term risk of falls in an incident Parkinson’s disease cohort: the Norwegian ParkWest study.
Hiorth YH, Alves G, Larsen JP, Schulz J, Tysnes OB, Pedersen KF.
J Neurol. 2016 Dec 20. doi: 10.1007/s00415-016-8365-z. [Epub ahead of print]
PMID: 28000003

Changes in insomnia subtypes in early Parkinson disease.
Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD.
Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003540.
PMID: 27986876

Impulsive and Compulsive Behaviors in Parkinson Disease: The Norwegian ParkWest Study.
Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF.
J Parkinsons Dis. 2016 Nov 30.
PMID: 27911342

Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.
Abdullah R, Patil KS, Rosen B, Pal R, Prabhudesai S, Lee S, Basak I, Hoedt E, Yang P, Panick K, Ho HP, Chang E, Tzoulis C, Larsen JP, Neubert TA, Alves G, Møller SG.
Mol Neurobiol. 2016 Nov 11.
PMID: 27837450

Measuring Life Satisfaction in Parkinson’s Disease and Healthy Controls Using the Satisfaction With Life Scale.
Løvereide L, Hagell P.
PLoS One. 2016 Oct 24;11(10):e0163931. doi: 10.1371/journal.pone.0163931.
PMID: 27776131

Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.
Bjornestad A, Tysnes OB, Larsen JP, Alves G.
Neurology. 2016 Oct 11;87(15):1599-1606.
PMID: 27590290

LRRK2 knockdown in zebrafish causes developmental defects, neuronal loss, and synuclein aggregation.
Prabhudesai S, Bensabeur FZ, Abdullah R, Basak I, Baez S, Alves G, Holtzman NG, Larsen JP, Møller SG.
J Neurosci Res. 2016 Aug;94(8):717-35. doi: 10.1002/jnr.23754. Epub 2016 Jun 5.
PMID: 27265751

Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
Førland MG, Öhrfelt A, Oftedal LS, Tysnes OB, Larsen JP, Blennow K, Zetterberg H, Alves G, Lange J.
Clin Chem Lab Med. 2016 Jul 30. pii: /j/cclm.ahead-of-print/cclm-2016-0409/cclm-2016-0409.xml. doi: 10.1515/cclm-2016-0409.
PMID: 27474841

Prodromal Markers in Parkinson's Disease: Limitations in Longitudinal Studies and Lessons Learned.
Heinzel S, Roeben B, Ben-Shlomo Y, Lerche S, Alves G, Barone P, Behnke S, Berendse HW, Bloem BR, Burn D, Dodel R, Grosset DG, Hu M, Kasten M, Krüger R, Moccia M, Mollenhauer B, Oertel W, Suenkel U, Walter U, Wirdefeldt K, Liepelt-Scarfone I, Maetzler W, Berg D.
Front Aging Neurosci. 2016 Jun 22;8:147. doi: 10.3389/fnagi.2016.00147. eCollection 2016.
PMID: 27445791

Biomarker Assessments to be Used in Longitudinal Studies.
Lerche S, Heinzel S, Alves GW, Barone P, Behnke S, Ben-Shlomo Y, Berendse H, Bloem BR, Burn D, Dodel R, Grosset DG, Hipp G, Hu MT, Kasten M, Krüger R, Liepelt-Scarfone I, Maetzler W, Moccia M, Mollenhauer B, Oertel W, Roeben B, Walter U, Wirdefeldt K, Berg D.
Front Aging Neurosci. 2016 May 27;8:121. doi: 10.3389/fnagi.2016.00121. eCollection 2016. N
PMID: 27303289

microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases.
Basak I, Patil KS, Alves G, Larsen JP, Møller SG.
Cell Mol Life Sci. 2016 Feb;73(4):811-27. doi: 10.1007/s00018-015-2093-x. Epub 2015 Nov 25. Review.
PMID: 26608596

Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson’s Disease.
Bjornestad A, Tysnes OB, Larsen JP, Alves G.
Parkinsons Dis. 2016;2016:1941034. doi: 10.1155/2016/1941034.
PMID: 27213080

Impact of Falls on Physical Activity in People with Parkinson’s Disease.
Hiorth YH, Larsen JP, Lode K, Tysnes OB, Godfrey A, Lord S, Rochester L, Pedersen KF.
J Parkinsons Dis. 2016;6(1):175-82. doi: 10.3233/JPD-150640.
PMID: 26639446

Risk and course of motor complications in a population-based incident Parkinson’s disease cohort.
Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G.
Parkinsonism Relat Disord. 2016 Jan;22:48-53. doi: 10.1016/j.parkreldis.2015.11.007.
PMID: 26585090


2015

A Proteomics Approach to Investigate miR-153-3p and miR-205-5p Targets in Neuroblastoma Cells.
Patil KS, Basak I, Pal R, Ho HP, Alves G, Chang EJ, Larsen JP, Møller SG.
PLoS One. 2015 Dec 3;10(12):e0143969. doi: 10.1371/journal.pone.0143969. eCollection 2015.
PMID: 26633009

Association of a BACE1 Gene Polymorphism with Parkinson’s Disease in a Norwegian Population.
Lange J, Lunde KA, Sletten C, Møller SG, Tysnes OB, Alves G, Larsen JP, Maple-Grødem J.
Parkinsons Dis. 2015;2015:973298. doi: 10.1155/2015/973298. Epub 2015 Dec 14.
PMID: 26788404

Parkinson's disease and age: The obvious but largely unexplored link.
Abdullah R, Basak I, Patil KS, Alves G, Larsen JP, Møller SG.
Exp Gerontol. 2015 Aug;68:33-8. doi: 10.1016/j.exger.2014.09.014. Epub 2014 Sep 26. Review.
PMID: 25261764

The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease.
Lill CM, Rengmark A, Pihlstrøm L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno G, Rujescu D, Schnack C, Shaw CE, Shaw PJ, Tumani H, Tysnes OB, Valladares O, Silani V, van den Berg LH, van Rheenen W, Veldink JH, Lindenberger U, Steinhagen-Thiessen E; SLAGEN Consortium, Teipel S, Perneczky R, Hakonarson H, Hampel H, von Arnim CA, Olsen JH, Van Deerlin VM, Al-Chalabi A, Toft M, Ritz B, Bertram L.
Alzheimers Dement. 2015 Apr 30.

Development of excessive daytime sleepiness in early Parkinson disease.
Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD.
Neurology. 2015 Jul 14;85(2):162-8.

HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia.
Tzoulis C, Zayats T, Knappskog PM, Müller B, Larsen JP, Tysnes OB, Bindoff LA, Johansson S, Haugarvoll K.
Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2268.

Fine mapping and resequencing of the PARK16 locus in Parkinson’s disease.
Pihlstrøm L, Rengmark A, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Dietrichs E, Toft M.
J Hum Genet. 2015 Jul;60(7):357-62.


2014

The factor structure of the UPDRS motor scores changes during early Parkinson’s disease.
Brakedal B, Tysnes OB, Skeie GO, Larsen JP, Müller B.
Parkinsonism Relat Disord. 2014 Jun;20(6):617-21.

CSF Aβ42 predicts early-onset dementia in Parkinson disease.
Alves G, Lange J, Blennow K, Andreasson U, Førland M, Tysnes OB, Larsen JP, Pedersen KF.
Neurology. 2014 Apr 18.


2013

Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease.
Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB.
Parkinsonism Relat Disord. 2013 Aug 2.

Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study.
Pedersen KF, Larsen JP, Tysnes OB, Alves G.
JAMA Neurol. 2013 Mar 25:1-7.

Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson’s disease.
Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, Dalaker TO, Kurz MW, Larsen JP, Somme JH, Thompson PM, Tysnes OB, Apostolova LG.
Mov Disord. 2013 Mar;28(3):302-10. doi: 10.1002/mds.25282. Epub 2013 Feb 13.

Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson’s disease.
Beyer MK, Bronnick KS, Hwang KS, Bergsland N, Tysnes OB, Larsen JP, Thompson PM, Somme JH, Apostolova LG.
J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):23-8.

Supportive evidence for 11 loci from genome-wide association studies in Parkinson’s disease.
Pihlstrøm L, Axelsson G, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Ohman E, Dietrichs E, Toft M.
Neurobiol Aging. 2013 Jun;34(6):1708.e7-13.

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson’s disease.
Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP.
J Neurol Neurosurg Psychiatry. 2013 May;84(5):537-43.

Autonomic symptoms and dopaminergic treatment in de novo Parkinson’s disease.
Müller B, Assmus J, Larsen JP, Haugarvoll K, Skeie GO, Tysnes OB.
Acta Neurol Scand. 2013 Apr;127(4):290-4.23.

Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study.
Skeie GO, Muller B, Haugarvoll K, Larsen JP, Tysnes OB.
Parkinsonism Relat Disord.2013 Jan;19(1):53-5.

Frequencies of falls and associated features at different stages of Parkinson’s disease.
Hiorth YH, Lode K, Larsen JP.
Eur J Neurol. 2013 Jan;20(1):160-6.

Treatment in early Parkinson’s disease: the Norwegian ParkWest study.
Tveiten OV, Skeie GO, Haugarvoll K, Müller B, Larsen JP, Tysnes OB.
Acta Neurol Scand. 2013 Aug;128(2):107-13.


2012 og tidligere

Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population.
Balafkan N, Tzoulis C, Müller B, Haugarvoll K, Tysnes OB, Larsen JP, Bindoff LA.
Mitochondrion. 2012 Nov;12(6):640-3.

Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease.
Pedersen KF, Alves G, Larsen JP, Tysnes OB, Møller SG, Brønnick K.
Am J Geriatr Psychiatry. 2012 Feb;20(2):142-8.

Subjective sleep problems in patients with early Parkinson’s disease.
Stefansdottir S, Gjerstad MD, Tysnes OB, Larsen JP.
Eur J Neurol. 2012 Dec;19(12):1575-81.

Fatigue in early Parkinson’s disease. Minor inconvenience or major distress?
Herlofson K, Ongre SO, Enger LK, Tysnes OB, Larsen JP.
Eur J Neurol. 2012 Jul;19(7):963-8.

Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease.
Pedersen KF, Alves G, Larsen JP, Tysnes OB, Møller SG, Brønnick K.
Am J Geriatr Psychiatry. 2012 Feb;20(2):142-8.


2011
Increased risk of leg motor restlessness but not RLS in early Parkinson disease.
Gjerstad MD, Tysnes OB, Larsen JP.
Neurology. 2011 Nov 29;77(22):1941-6.

Ventricular enlargement and mild cognitive impairment in early Parkinson’s disease.
Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS, Tysnes OB, Aarsland D, Larsen JP.
Mov Disord. 2011 Feb 1;26(2):297-301.

Verbal memory in drug-naive, newly diagnosed parkinson’s disease. The retrieval deficit hypothesis revisited.
Brønnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP.
Neuropsychology. 2011 Jan;25(1):114-24.

Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s disease: Frequent but mild.
Müller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; for The ParkWest Study Group.
Mov Disord. 2011 Jan;26(1):65-72.


2010
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.
Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M.
Neurology. 2010 Sep 21;75(12):1062-9.

Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson’s disease.
Skeie GO, Muller B, Haugarvoll K, Larsen JP, Tysnes OB.
Mov Disord. 2010 Sep 15;25(12):1847-52.

Are dysautonomic and sensory symptoms present in early Parkinson’s disease?
Tysnes OB, Müller B, Larsen JP.
Acta Neurol Scand Suppl. 2010;(190):72-7.

CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson’s Disease: the Norwegian ParkWest study.
Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
J Neurol Neurosurg Psychiatry.  2010 Oct;81(10):1080-6.

“The role of APOE alleles in newly diagnosed PD patients in Western Norway. The Norwegian ParkWest study”.
Vefring H, Haugarvoll K, Tysnes OB, Larsen JP, Kurz MW; for the Norwegian ParkWest Study group.
Acta Neurol Scand. 2010 Dec;122(6):438-41.

Gray matter correlations of cognition in incident Parkinson’s disease.
Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, Bronnick K, Tysnes OB, Antulov R, Dwyer MG, Aarsland D.
Mov Disord. 2010 Apr 15;25(5):629-33.

Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study.
Leiknes I, Tysnes OB, Aarsland D, Larsen JP.
Acta Neurol Scand. 2010 Dec;122(6):418-24.

Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study.
Pedersen KF, Alves G, Brønnick K, Aarsland D, Tysnes OB, Larsen JP.
J Neurol. 2010 Feb;257(2):217-23.


2009
Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study.
Vossius C, Nilsen OB, Larsen JP.
Drugs Aging. 2009;26(11):973-80.

“Brain Atrophy and White Matter Hyperintensities in Early Parkinson’s Disease. The Norwegian ParkWest study”.
Dalaker TO, Larsen JP, Bergsland N, Beyer MK, Alves G, Dwyer MG, Tysnes OB, Benedict RH, Kelemen A, Bronnick K, Zivadinov R.
Mov Disord. 2009 Nov 15;24(15):2233-41.

White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson’s disease.
Dalaker TO, Larsen JP, Dwyer MG, Aarsland D, Beyer MK, Alves G, Bronnick K, Tysnes OB, Zivadinov R.
Neuroimage. 2009 Oct 1;47(4):2083-9.

The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease.
Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP.
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30.

Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study.
Alves G, Müller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, Tysnes OB, Larsen JP.
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):851-7.

Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.
Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group.
Neurology. 2009 Mar 31;72(13):1121-6.